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A B S T R A C T
Recombinant proteins produced by baculovirus (BV) expression systems contain residual BV after crude
puriﬁcation. We studied adjuvant eﬀect of BV on antibody and T cell responses against two model antigens,
monomeric ovalbumin (OVA) protein and oligomeric norovirus (NoV) virus-like particles (VLPs). BALB/c mice
were immunized intradermally with OVA alone or OVA formulated with live or inactivated BV, and VLP
formulations comprised of chromatographically puriﬁed NoV GII.4 VLPs alone or mixed with BV, or of crude
puriﬁed VLPs containing BV impurities from expression system. Live BV improved immunogenicity of NoV
VLPs, sparing VLP dose up to 10-fold. Moreover, soluble OVA protein induced IgG2a antibodies and T cell
response only when co-administered with live BV. BV adjuvant eﬀect was completely abrogated by removal or
inactivation of BV. These ﬁndings support the usage of crude puriﬁed proteins containing residual BV as vaccine
antigens.
1. Introduction
Numerous currently licensed vaccines are based on live attenuated
or inactivated pathogens, but there is a tendency towards development
of safer non-replicating subunit protein vaccines. Therefore, novel
vaccines under development are often based on recombinant proteins.
Production of recombinant proteins results in substantial amounts of
impurities related to the expression technology utilized in the produc-
tion process. Impurities derived from baculovirus (BV) expression
system include live BV, baculoviral dsDNA genome, and baculoviral
proteins, particularly envelope glycoprotein gp64 (Hervas-Stubbs et al.,
2007; Huhti et al., 2013; Lappalainen et al., 2016).
At present, several recombinant protein vaccines based on BV
expression technology are commercially available, including human
vaccines against human papilloma virus (Cervarix®, GlaxoSmithKline)
and inﬂuenza virus (Flublok®, Protein Sciences), as well as veterinary
vaccines against classical swine fever virus (Porcilis Pesti®, MSD
Animal Health) and porcine circovirus type 2 (Porcilis® PCV, MSD
Animal Health; CircoFLEX®, B. Ingelheim). Moreover, other potential
vaccine candidates are in advanced stages of clinical trials, such as
those directed against norovirus (NoV) (Vesikari and Blazevic, 2015;
Atmar et al., 2016). Because of a strict regulatory control, substantial
eﬀorts are undertaken to purify proteins for use as human vaccine
antigens. On the other hand, impurities related to BV expression
system have commonly been associated with strong immunostimula-
tory eﬀects. BV has been reported to possess adjuvant properties,
promoting humoral and cellular immune responses against foreign
antigens as well as activation of innate immune responses by inducing
type I and II IFNs (Gronowski et al., 1999; Abe et al., 2005; Hervas-
Stubbs et al., 2007; Suzuki et al., 2010). Moreover, wild-type BV has
contributed to protection in mice from a lethal challenge of encepha-
lomyocarditis virus (EMCV) (Gronowski et al., 1999), inﬂuenza virus
H1N1 (Abe et al., 2003) and foot-and-mouth disease virus (FMDV)
(Molinari et al., 2011; Quattrocchi et al., 2013), where protection was
directly associated with immune responses elicited by BV.
In the history of human vaccines, the most successful in disease
control and eradication have been those employing live attenuated
viruses (e.g. polio, measles, yellow fever, inﬂuenza virus, rotavirus)
(Minor, 2015). As these viruses can still infect cells and replicate to a
certain limit, the live attenuated vaccines are able to induce fast and
durable protective immunity. Instead, recombinant proteins are gen-
erally weakly immunogenic unless administered with an external
adjuvant (Bachmann and Jennings, 2010; Josefsberg and Buckland,
2012). Due to the adjuvant and antiviral properties of BV described
above, residual BV originating from the expression system could be
considered as an adjuvant to improve immunogenicity of these
proteins.
In the present study, we investigated adjuvant eﬀect of BV on
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antibodies and T cell mediated immune responses against two diﬀerent
model antigens, a soluble monomeric ovalbumin (OVA) protein and
NoV virus-like particles (VLPs). We demonstrate here that live BV
promoted immunogenicity of both OVA and NoV VLPs, and the eﬀect
was abolished by virus inactivation.
2. Materials and methods
2.1. Antigenic formulations
2.1.1. Ovalbumin
Lyophilized OVA (Albumin from chicken egg white; Sigma) was
dissolved at 2 mg/mL in phosphate-buﬀered saline (PBS; Lonza,
Verviers, Belgium). The stock was sterilized with a 0.2 µm ﬁlter prior
to use.
2.1.2. Production of mock BV
Live BVs were generated in Bac-to-Bac BV expression system
(Invitrogen, Carlsbad, CA) in Sf9 insect cells and puriﬁed on sucrose
gradients and ultracentrifugation as previously described (Huhti et al.,
2013). The infectious BV titer of the mock BV, expressed as plaque-
forming unit per mL (pfu/mL), was determined using a BacPAK™
Rapid Titer Kit (Clontech Laboratories, Mountain View, CA) according
to the manufacturer's instructions.
The inactivated BV (IBV) was prepared from live BV by heat
inactivation at 60 °C for 1 h. The inactivation of live BVs was conﬁrmed
by BacPAK™ Rapid Titer Kit.
2.1.3. Production of recombinant NoV VLPs
NoV GII.4 (Reference strain accession number AF080551) VLPs
were produced in BV–insect cell expression system, as described in
details elsewhere (Huhti et al., 2010). GII.4 VLPs were crudely puriﬁed
on two discontinuous sucrose gradients and ultracentrifugation as
described earlier (Huhti et al., 2010). In order to obtain highly puriﬁed
proteins, the crude GII.4 VLPs were further puriﬁed using a combina-
tion of two-step anion exchange (HiTrap Q, GE Healthcare, Uppsala,
Sweden) chromatography procedures (Huhti et al., 2013).
The purity, identity and morphology of the crude and chromato-
graphically puriﬁed NoV GII.4 VLPs were determined using previously
published procedures (Huhti et al., 2013; Blazevic et al., 2016), such as
SDS-PAGE followed by PageBlue™ staining (Thermo Fisher Scientiﬁc
Inc., Rockford, IL) or immunoblotting with anti-BV gp64 (Santa Cruz
Biotechnology Inc, Santa Cruz, CA), Quant-it dsDNA Broad-Range
Assay Kit (Invitrogen), Limulus Amebocyte Lysate Assay (Lonza,
Walkersville, MD), BacPAK™ Rapid Titer Kit, and transmission
electron microscopy (FEI Tecnai F12, Philips Electron Optics,
Holland) after negative staining.
2.1.4. Synthetic peptides
A murine CD4+ T cell epitope (323ISQAVHAAHAEINEAGR339,
InvivoGen, San Diego, CA) derived from chicken OVA (McFarland
et al., 1999) was used to test OVA-speciﬁc T cell responses by enzyme-
linked immunospot (ELISPOT) interferon gamma (IFN-γ) assay.
Rotavirus-speciﬁc 14-mer R6-1 peptide (289RLSFQLMRPPNMTP302)
synthetized by Proimmune LTd. (Oxford, UK) was used as an irrelevant
negative control peptide in the assays.
Seventy-six 18-mer overlapping peptides representing the entire
539 amino acid (aa) sequence of GII.4–1999 NoV VP1 were custom
synthetized (Synpeptide Co. Ltd, Shanghai, China) and pooled (Malm
et al., 2016b, 2016c). A complete peptide pool (named 99 pool) as well
as an individual peptide 99-50 (344TRAHKATVSTGSVHFTPK361)
corresponding to the previously identiﬁed murine 18-mer NoV-speciﬁc
CD4+ T cell epitope (Malm et al., 2016c) were used to test NoV-speciﬁc
T cell responses by the ELISPOT.
2.2. Animal immunization and sample preparation
Female BALB/c OlaHsd mice, aged 6 weeks, were purchased from
Envigo (Horst, the Netherlands). The mice were randomly divided into
eight groups (Gr I–VIII), acclimatized under controlled speciﬁc patho-
gen-free conditions for one week prior to the start of the experiment,
and maintained throughout the study period with food and water
provided ad libitum. Animals (3–4 mice/experimental group) were
immunized twice (at study weeks 0 and 3) intradermally (i.d.) at the
base of the tail with 50 µl of diﬀerent antigenic formulations, each
formulation diluted in sterile PBS to contain the indicated dose of
immunogen (Table 2). Control group received no antigen (PBS only).
Immunizations were performed under general anesthesia induced with
a mixture of Hypnorm® (VetaPharma Limited, Leeds, UK) and
Dormicum® (Roche Pharma AG, Grenzach-Wyhlen, Germany).
To test the kinetics of the antibody responses in sera, tail blood
samples (diluted 1:200 in PBS at the time of collection) were collected
at study weeks 0 (pre-bleed, non-immune sera) and 2 or 3. Mice were
sacriﬁced 35 days after the ﬁrst immunization (at study week 5) by
decapitation, when whole blood and lymphoid tissues were collected.
Preparation of blood samples and a single-cell suspension from the
spleen of each mouse was conducted according to the published
procedures of our laboratory (Tamminen et al., 2012). All of the
experimental procedures carried out were in accordance with the
regulations and guidelines of the Finnish National Experiment Board
(permission numbers ESLH-2009–06698/Ym-23 and ESAVI/4106/
04.10.03/2012) and all eﬀorts were made to minimize animal suﬀer-
ing. Animals were monitored for physical conditions throughout the
experiment.
2.3. Detection of serum IgG and IgG subtypes by ELISA
2.3.1. OVA- and NoV GII.4-speciﬁc IgG, IgG1 and IgG2a responses
Sera of experimental mice were tested in ELISA for the presence of
OVA- or NoV GII.4-speciﬁc IgG, IgG1 and IgG2a antibodies as
described in detail elsewhere (Blazevic et al., 2011; Tamminen et al.,
2012). Brieﬂy, 96-well half-area polystyrene plates (Corning Inc,
Corning, NY) were coated with OVA (200 ng/well for IgG, 100 ng/well
for IgG subtypes) or GII.4 VLPs (20 ng/well). Serum samples at 1:200
dilution or serially diluted two-fold were added on the plates, and the
bound antibodies were detected with horseradish peroxidase (HRP)-
conjugated anti-mouse IgG (Sigma-Aldrich, St. Louis, MO), IgG1
(Invitrogen) or IgG2a (Invitrogen) and SIGMA FAST OPD substrate
(Sigma-Aldrich). Optical density (OD) values at 490 nm (OD490) were
measured by a microplate reader (Victor2 1420; PerkinElmer,
Waltham, MA). A sample was considered positive if the OD490 was
above the cut-oﬀ value (mean OD490 of the control mice + 3 × SD) and
OD490 > 0.1. The end-point titers were deﬁned as the reciprocal of the
highest dilution with an OD490 above the cut-oﬀ value. A titer of 100
was assigned to negative samples, being a half of the starting serum
dilution.
2.3.2. BV-speciﬁc IgG response
Induction of BV-speciﬁc IgG response was evaluated by testing
1:200 diluted serum samples of individual experimental mice by ELISA
as described above for OVA- and NoV-speciﬁc responses, but the
microtiter plates were coated with mock BV (100 ng/well).
2.4. Antibody avidity assay
The avidity of OVA- and NoV-speciﬁc IgG antibodies was deter-
mined in 1:200 diluted serum samples according to the previously
published avidity assay (Tamminen et al., 2012) using an extra urea
incubation step to remove the low-avidity antibodies. Results were
expressed as avidity index: (OD490 with urea/OD490 without urea) ×
100%.
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2.5. NoV blocking assay
To examine the ability of serum antibodies to block the binding of
NoV VLPs to a cellular histo-blood group antigen (HBGA) receptor, pig
gastric mucin (PGM) type III (Sigma Chemicals) was used as a source
of HBGAs according to the published procedure (Lindesmith et al.,
2012) with slight modiﬁcations (Malm et al., 2017). Group-wise pooled
two-fold serum dilutions (starting at 1:50) were pre-incubated for 1 h
at 37 °C with 0.1 µg/mL of NoV GII.4 VLPs before plating on 96-
microwell plates coated with 2.5 µg/mL of PGM. Maximum binding
was determined with NoV VLPs without serum. Bound VLPs were
detected with human NoV antiserum, an anti-human IgG-HRP (Novex)
and Sigma FAST OPD substrate, followed by determination of OD490
readings with a microplate reader (Victor2 1420). Blocking index (%)
was calculated as follows: 100% − [OD490 (wells with serum)/ OD490
(wells without serum, maximum binding) × 100%]. Results were
expressed as the blocking titer 90 (BT90), the reciprocal of the highest
serum dilution blocking ≥90% of the VLPs binding to the HBGAs.
2.6. Cell-mediated immune responses
2.6.1. NoV and OVA-speciﬁc ELISPOT IFN-γ
Antigen-speciﬁc T cell responses were analyzed using a slightly
modiﬁed ELISPOT IFN-γ assay (Tamminen et al., 2013). Group-wise
pooled splenocytes (0.2×106 cells/well) were plated on Multiscreen
HTS-IP ﬁlter plates (Millipore, Billerica. MA) coated with a monoclonal
anti-mouse IFN-γ antibody (Mabtech AB, Nacka Strand, Sweden) at
5 µg/mL. For detection of OVA-speciﬁc IFN-γ producing cells, cell were
stimulated in duplicates with OVA peptide (0.2, 1, 2, and 4 µg/mL) or
R6-1 peptide (negative control, 4 µg/mL). To detect NoV-speciﬁc IFN-
γ producing cells, cells were stimulated in duplicates with GII.4–99
peptide pool (2 µg/mL), GII.4 99-50 peptide (4 µg/mL) or OVA peptide
(negative control, 4 µg/mL). Background control (culture medium;
RPMI 1640 supplemented with 10% FBS, 100 U/mL penicillin,
100 µg/mL streptomycin, 50 µM 2-mercaptoethanol, and 2 mM L-
glutamine; all from Sigma-Aldrich) and cell viability control (10 μg/
mL T cell mitogen Concanavalin A; Sigma-Aldrich) were tested in each
assay. After overnight incubation at 37 °C, IFN-γ secretion was
detected with biotinylated anti-mouse IFN-γ monoclonal antibody
and alkaline phosphatase -conjugated streptavidin (both from
Mabtech AB). The spots developed with BCIP/NBT (5-bromo-4-
chloro-3-indolyl-phosphate) substrate (Mabtech AB) were counted by
ImmunoSpot® automatic CTL analyzer (CTL-Europe GmbH, Bonn,
Germany). The results were expressed as mean spot-forming cells
(SFC)/106 splenocytes of duplicate wells. An increase of at least twice
above the negative control peptide SFC counts was considered as a
positive result.
2.6.2. BV-speciﬁc ELISPOT IFN-γ
BV-speciﬁc T cell responses were assessed by ELISPOT IFN-γ assay
as described above, except group-wise pooled splenocytes (1×105 cells/
well) of immunized and control mice were stimulated with mock BV
(1×104–106 pfu/well).
2.7. Statistical analyses
The Mann-Whitney U-test and Kruskal-Wallis test were employed
to determine the statistical diﬀerences between the non-parametric
observations of two or more independent groups. All analyses were
conducted by IBM SPSS Statistics for Windows (IBM Corp., Armonk,
NY), Version 23.0. The statistically signiﬁcant diﬀerence was deﬁned as
p ≤ 0.05.
3. Results
3.1. Characterization of NoV VLPs used for immunization
Crude and chromatographically puriﬁed NoV GII.4 VLPs were
characterized for purity, identity and morphology prior to use for
immunizing animals. Fig. 1A shows SDS-PAGE, where NoV capsid
protein appeared as a doublet band, typical for the capsid GII.4 protein
(Huhti et al., 2010), in both VLP preparations. Instead, a faint band
corresponding to the size of the BV envelope gp64 protein, was
observed only in the crude preparation (Fig. 1A). The presence of
gp64 in the crude puriﬁed VLPs was conﬁrmed by immunoblotting
(Table 1) with anti-BV gp64. Furthermore, the presence of BV was
further tested by determining the infectious BV titers (Table 1).
Although crude VLPs are produced by the standard methods as
described above, diﬀerent production lots have inconsistent quantity
of BV (data not show). Moreover, crude and chromatographically
Fig. 1. Characterization of NoV GII.4 VLPs used for immunizations. (A) Purity and integrity analysis of crude (lane 1) and chromatographically puriﬁed (lane 2) NoV GII.4 VLPs with
SDS-PAGE followed by PageBlue staining. Lane M, molecular weight marker. (B) Electron microscopy images of crude (panel 1) and chromatographically puriﬁed (panel 2) NoV GII.4
VLPs corresponding to the respective SDS-PAGE lanes 1 and 2 (A). Protein structures were examined after negative staining with 3% uranyl acetate. Images were observed at 18500 ×
magniﬁcation.
Table 1
Specifications and analysis of impurities related to the expression system in the crude




Morphologya VLPs (~38 nm) VLPs (~38 nm)
Infectious BV (pfu/mL)b 107 0
BV gp64c + –
Total DNA (ng dsDNA/10 µg
protein)d
< 30 < 10
Endotoxin (EU/10 µg protein)e < 0.1 < 0.1
a Electron microscopy after negative staining.
b BacPAK™ Rapid Titer Kit.
c SDS-PAGE followed by immmunoblotting with anti-BV gp64.
d Quant-it dsDNA Broad-Range Assay Kit.
e Limulus Amebocyte Lysate Assay.
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puriﬁed NoV GII.4 VLPs were morphologically similar as indicated by
EM analysis (Fig. 1B). Hence, the chromatographic puriﬁcation did not
aﬀect morphology or integrity of VLPs, but removed impurities related
to the BV expression system, as virtually no traces of dsDNA genome,
live BV or baculoviral proteins were detected in the pure VLP
preparations (Table 1).
3.2. Assessment of physical condition
Regardless of the antigenic formulation used for immunization, all
animals remained healthy and gained weight during the study period
(Table 2). No diﬀerence in body weight between the experimental
groups was observed (p=0.98).
3.3. Enhancement of OVA-speciﬁc serum antibody responses by BV
Possible inﬂuence of BV on OVA-speciﬁc immune responses was
investigated by immunizing the experimental mice on a two-dose
schedule with 45 μg of OVA alone or together with live BV or IBV at
an interval of three weeks (Table 2). Two immunizations of each
formulation elicited considerable level of total anti-OVA IgG antibodies
(Fig. 2A). Similar IgG responses with end-point titers of 12800 were
induced, when OVA was administered alone or together with IBV.
Instead, co-administration of OVA with live BV resulted in 16-fold
increase in the IgG titer (end-point titer 204800). No OVA-speciﬁc
antibodies were detected in sera of control mice.
Determination of OVA-speciﬁc IgG subtype IgG1 and IgG2a titers,
representing Th2- and Th1-type responses, revealed induction of IgG1
antibodies by each OVA formulation (Fig. 2B) but induction of
signiﬁcant IgG2a antibodies only by the OVA formulations containing
live BV (Fig. 2C). Co-administration of OVA with BV generated ≥16-
fold higher levels of IgG1 (end-point titer 409600) compared to
administration of OVA alone or together with IBV. No IgG2a was
detected after immunization of mice with OVA alone while formulation
with IBV induced very low level of IgG2a, probably due to incomplete
inactivation of BV (Table 2) containing 103 pfu. In contrast, combina-
tion of OVA and live BV induced very high anti-OVA IgG2a antibodies
(end-point titer 102400).
Serum samples from individual mice were further assayed for the
avidity of OVA-speciﬁc IgG antibodies. Immunization with OVA or
combination of OVA and IBV induced IgG antibodies with low avidity
(respective avidity indices 21.0 ± 5.8% and 10.4 ± 1.3%), but inclusion
of BV in the formulation elevated the avidity of antibodies (avidity
index 47.5 ± 8.8%) (Fig. 2D). No statistical diﬀerence (p=0.083) was
detected in the avidity indices between the groups immunized with
OVA alone and a combination of OVA and BV, but the avidity was
signiﬁcantly greater (p=0.021) in mice co-administered with OVA and
BV compared to the mice co-administered with OVA and IBV.
3.4. Induction of OVA-speciﬁc T cell responses by live BV
The diﬀerence in induction of Th1 responses by OVA formulations
with or without BV was further studied measuring Th1-type cytokine
IFN-γ production from the splenocytes of immunized mice (Fig. 3).
Cells from the mice receiving OVA and BV responded with considerable
IFN-γ release to ex vivo stimulation with the 17-mer OVA-speciﬁc
peptide, representing a CD4+ T cell epitope (Fig. 3). On the contrary,
immunization with OVA alone or together with IBV did not induce
OVA-speciﬁc IFN-γ production by T cells (p=0.020 for both) (Fig. 3).
No response to the negative control peptide R6-1 was detected in any of
the study groups (data not shown).
3.5. Improved immunogenicity of NoV VLPs by BV
To examine eﬀect of BV on NoV GII.4-speciﬁc humoral immune
responses, mice were immunized twice with 1 or 10 µg doses of pure
NoV GII.4 VLPs, 1 µg dose of pure VLPs combined with BV or 1 µg
dose of crude-puriﬁed VLPs containing BV (Table 2). After the ﬁrst
immunization, 1 µg of pure VLPs induced signiﬁcantly lower IgG
response in comparison with other VLP formulations (p=0.003),
whereas 10 µg dose of pure VLPs as well as both VLP formulations
containing BV resulted in similar responses (p=0.221) at study week 2
or 3 (Fig. 4A). Two immunizations of each antigenic formulation
containing NoV GII.4 VLPs elicited high level of total anti-GII.4 IgG
antibodies at week 5 (Fig. 4A). Control mice remained negative for
GII.4-speciﬁc total IgG during the study period (Fig. 4A).
Determination of IgG subtype titers showed induction of both Th2-
and Th1-type response by each GII.4 VLP formulation. Similar IgG1
responses were elicited, irrespective of the presence or absence of BV
(Fig. 4B). Instead, administration of the GII.4 VLPs with BV resulted in
8-fold higher IgG2a titers (end-point titers of 204800) compared with
administration of 1 or 10 µg doses of pure VLPs (end-point titers of
25600) (Fig. 4C). No GII.4-speciﬁc IgG subtype antibodies were
detected in sera of control mice (Fig. 4B and C).
3.6. Eﬀect of BV on functionality of GII.4-speciﬁc antibodies
Testing of individual immune sera for the avidity of GII.4-speciﬁc
IgG antibodies indicated, that immunization with 1 µg of pure VLPs
induced antibodies with a considerably lower (p=0.029) avidity (avidity
index 18.4 ± 7.9%) as compared with antibodies induced with a
combination of VLPs and BV (67.2 ± 10.3%) or crude-puriﬁed VLPs
with residual BV (60.9 ± 3.9%) (Fig. 5A). No statistical diﬀerence
(p=0.624) was observed between the groups of mice immunized with
10 µg of pure VLPs (avidity index 48.7 ± 8.9%) and the two VLP
formulations containing BV (Fig. 5A).
The functionality of the GII-4-speciﬁc antibodies was further
examined by measuring the blocking potential of the pooled immune
sera, where PGM was employed as the HBGA source for GII.4 VLP
binding. Each VLP formulation induced antibodies able to block ≥90%
of the VLP binding (Fig. 5B). However, 4-fold higher blocking titers
BT90 were observed in mice immunized with VLPs combined with BV
or crude-puriﬁed VLPs containing BV, compared with mice immunized
with 1 µg dose of pure VLPs (Fig. 5B). Moreover, administration with
10 µg dose of pure VLPs resulted in antibodies with 2-fold greater
BT90 as compared with antibodies induced with lower dose of pure
VLPs (Fig. 5B).
3.7. Enhancement of GII.4-speciﬁc T cell responses by BV
Induction of T cell responses by NoV GII.4 VLP formulations was
Table 2











I OVA 45 µg 17.9 ± 0.3 21.0 ± 0.8
II OVA + BV 45 µg +
107 pfu
17.4 ± 1.1 20.6 ± 1.2
III OVA + IBV 45 µg +
103 pfu
17.9 ± 1.4 21.4 ± 1.8
IV GII.4 VLPs 1 µg 17.9 ± 0.9 20.5 ± 1.0
V GII.4 VLPs 10 µg 17.5 ± 0.4 20.5 ± 0.5
VI GII.4 VLPs + BV 1 µg + 107
pfu
17.3 ± 4.3 21.1 ± 3.9
VII Crude GII.4 VLPs 1 µg (105
pfu)
17.2 ± 1.0 20.8 ± 2.1
VIII PBS – 17.8 ± 0.6 20.7 ± 0.5
a Mean weight +/− SD per experimental group of mice at study week 0 (prior to
immunization).
b Mean weight +/− SD per experimental group of mice at study week 5.
S. Heinimäki et al. Virology 511 (2017) 114–122
117
characterized by analyzing Th1-type cytokine IFN-γ production from
the splenocytes of experimental mice. Splenocytes from the mice
receiving 1 µg of pure GII.4 VLPs did not produce IFN-γ in response
to any stimulation (Fig. 6). Instead, immunization of mice with all
other VLP formulations elicited a robust IFN-γ response, when
stimulated with the 18-mer 99-50 peptide representing a NoV-speciﬁc
CD4+ T cell epitope, or with 99 peptide pool representing the entire
GII.4–1999 NoV VP1 (Fig. 6 and data not shown). Ten µg dose of pure
VLPs induced similar quantities of IFN-γ secreting cells to 1 µg of VLPs
combined with BV (p=0.08) as well as 1 µg of crude-puriﬁed VLPs
containing BV (p=0.885). Negative control OVA peptide stimulated no
IFN-γ production by the cells from any of the experimental groups
(Fig. 6).
3.8. Induction of BV-speciﬁc antibodies and T cell responses
Induction of BV-speciﬁc IgG response was evaluated in serum
samples of mice immunized with OVA formulations (groups I-III,
Table 2). As expected, addition of live BV or IBV to the OVA
formulation induced BV-speciﬁc responses (p=0.015). No BV response
was elicited immunizing with OVA alone, but considerable levels of BV-
speciﬁc antibodies were induced, when OVA was co-administered with
BV or IBV (Fig. 7A). No diﬀerence in antibody levels was noted whether
OVA was administered with BV or IBV (p=0.149).
Induction of BV-speciﬁc T cell responses was studied measuring
IFN-γ production from the splenocytes of the experimental groups.
Cells from the mice receiving OVA alone did not produce IFN-γ in
response to stimulation with BV (Fig. 7B). Instead, immunizations of
mice with formulations containing live BV elicited high IFN-γ response
(Fig. 7B). Moreover, low levels of IFN-γ were induced by co-adminis-
tration of OVA with IBV, which were substantially lower compared with
the responses induced by live BV formulation (p=0.019). No BV-
speciﬁc IFN-γ response was detected by the cells of negative control
mice (Fig. 7B).
4. Discussion
Several reports have shown live BV to have strong adjuvant
properties, promoting adaptive immune responses against co-adminis-
tered antigen and activation of innate immunity (Abe et al., 2003;
Fig. 2. OVA-speciﬁc serum IgG responses. End-point titrations of anti-OVA IgG (A), IgG1 (B) and IgG2a (C) antibodies of group-wise pooled termination sera of mice immunized with
OVA alone or formulated with BV. Control mice received PBS only. Mean titration curves with standard errors of duplicate wells are shown. (D) Mean avidity indices (%) with standard
error of the means of serum OVA-speciﬁc IgG antibodies.
Fig. 3. OVA-speciﬁc T cell responses. Diﬀerent concentrations of an OVA-speciﬁc
peptide were employed to stimulate IFN-γ production from the group-wise pooled
splenocytes of mice immunized with OVA alone or together with BV or IBV. Mean IFN-γ
spot-forming cells (SFC)/106 splenocytes of duplicate wells with standard errors of the
means are shown.
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Hervas-Stubbs et al., 2007; Molinari et al., 2011; Margine et al., 2012;
Quattrocchi et al., 2013). The adjuvant and antiviral properties of BV
make it an interesting tool to be considered in improvement of
immunological responses to vaccine antigens. This study was designed
to investigate adjuvant eﬀect of BV on adaptive immune responses
against two diﬀerent model antigens, monomeric OVA protein and
oligomeric NoV VLPs. We found signiﬁcant diﬀerences between the
immune responses triggered by these proteins alone or formulated with
BV in terms of antigen-speciﬁc antibody kinetics and titers, IgG
antibody subtypes, induction of T cell responses, and importantly,
functionality of the induced antibody responses. The diﬀerences were
clearly associated with the presence of live BV in the preparations and
not the structural or morphological diﬀerences (Fig. 1), as removal and
inactivation of BV abrogated the responses.
The exact mechanism through which BV exerts its adjuvant
behavior is not fully elucidated. Accordingly, mannose-binding resi-
dues in gp64 have been proposed to interact with the mannose receptor
expressed on macrophages and dendritic cells (DCs) (Abe et al., 2003).
Although mannose receptor plays an important role in host defense
and induction of innate immunity, several evidence contradicts gp64 as
the main factor in the stimulatory activities of BV (Abe et al., 2005;
Hervas-Stubbs et al., 2007). Instead, gp64-mediated uptake of BVs and
recognition of unmethylated CpG sequences within baculoviral DNA by
Toll-like receptor 9 (TLR9)/MyD88 dependent and independent path-
ways have been suggested to be necessary for the activation of innate
immune responses (Abe et al., 2005, 2009). BV is a potent inducer of
IFN-α and IFN-β (Gronowski et al., 1999; Abe et al., 2005; Hervas-
Stubbs et al., 2007) but also other cytokines of relevance, most notably
IFN-γ (Suzuki et al., 2010). Adjuvant activity is primarily mediated by
the production of IFN-α and IFN-β by immune cells (Abe et al., 2005;
Fig. 4. NoV-speciﬁc serum IgG responses. (A) Kinetics of NoV GII.4-speciﬁc total IgG
antibodies in serum samples of mice immunized with 1 or 10 µg of pure NoV GII.4 VLPs,
1 µg of pure VLPs combined with BV or 1 µg of crude-puriﬁed VLPs containing BV at
weeks 0 and 3. Control mice received PBS only. Group mean OD490 values with standard
error of the means of tail blood samples collected at study weeks 0 (pre-immune sera)
and 2 or 3 as well as termination sera at week 5 are shown. End-point titrations of anti-
GII.4 IgG1 (B) and IgG2a (C) subtype antibodies of group-wise (4 mice/group) pooled
termination sera. Mean titration curves with standard errors of duplicate wells of up to 2
independent experiments are shown.
Fig. 5. Avidity and blocking antibody titers of mice immunized with NoV GII.4 VLP formulations. (A) Mean avidity indices (%) with standard error of the means of GII.4-speciﬁc IgG
antibodies in termination sera of immunized groups. (B) Antibody titers of group-wise pooled sera blocking ≥90% (BT90) of the VLPs binding to the HBGAs.
Fig. 6. NoV GII.4-speciﬁc T cell responses. NoV GII.4–1999 –speciﬁc 99 peptide pool
and a single 99-50 peptide were used to stimulate IFN-γ production from the group-wise
pooled splenocytes of mice immunized with 1 µg of pure NoV GII.4 VLPs or 1 µg of pure
VLPs combined with BV. Culture medium (CM) as well as an OVA peptide were used as
negative controls. Mean IFN-γ spot-forming cells (SFC)/106 splenocytes of duplicate
wells with standard errors of the means are shown.
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Hervas-Stubbs et al., 2007), probably due to the ability of type I IFNs to
improve B cell as well as T cell responses (Le Bon et al., 2001, 2003;
Deal et al., 2013).
The current study demonstrates that live BV has desirable features
attributed to classical adjuvants, which work to spare the dose of the
antigen and improve the immune responses. We detected a consider-
ably higher immunogenicity of both antigens, OVA and NoV VLPs,
when formulated with BV. Importantly, BV was able to spare the dose
of the NoV VLPs used for immunization. In addition, BV acted to
promote both Th1- and Th2-type responses without skewing the
overall immune response in any particular direction. However, BV
could be considered a potent Th1-type adjuvant, as OVA protein was
capable of inducing antigen-speciﬁc IgG2a immunoglobulin subtype
only when co-administered with BV. Consistent with this observation,
Margine and co-workers (Margine et al., 2012) reported, that residual
BV in antigenic formulations biases the isotype distribution of the
antibody response towards the IgG2a immunoglobulin subtype, sug-
gesting stimulation of cell-mediated responses. In here, the BV
adjuvant eﬀect was strongly aﬀected by the removal or inactivation of
BVs, indicating that the adjuvant properties were due to the presence of
live BV. This is not surprising, as BV inactivation has been shown to
completely abrogate immunopotentiation eﬀect, partly due to abol-
ished production of type I IFNs (Hervas-Stubbs et al., 2007), which are
generated in response to live viruses (Goodbourn et al., 2000).
Antibodies with high avidity have been shown to promote eﬃcient
virus neutralization (Rockx et al., 2005; Puschnik et al., 2013). These
antibodies have also been associated with protection from some viral
infections, including vesicular stomatitis virus (VSV) (Salmi, 1991;
Bachmann et al., 1997). Moreover, previous data by our group
demonstrated that children with high-avidity anti-NoV IgG antibodies
had fewer NoV infections than children with low-avidity antibodies
(Nurminen et al., 2011). The present study shows that BV was able to
induce functionally eﬃcient humoral response, as live BV increased the
avidity of serum IgG antibodies against co-administered OVA protein
and NoV VLPs. Furthermore, NoV has been shown to use HBGAs,
complex carbohydrates found on red blood cells, mucosal epithelial
cells and as secreted free antigens in body ﬂuids, as cellular attachment
factors or receptors (Harrington et al., 2002; Marionneau et al., 2002;
Huang et al., 2003). Anti-NoV antibodies which block binding of NoV
VLPs to the HBGAs are considered correlate of protection against NoV
infection (Harrington et al., 2002; Reeck et al., 2010; Nurminen et al.,
2011; Malm et al., 2014). Our results demonstrate that administration
of GII.4 VLPs in a combination with BV considerably increased the
blocking potential of these antibodies.
Although the present study did not explore the induction of innate
immunity, we hypothesize that following i.d. immunization BV is taken
up by immature DC in the skin, and induces maturation and activation
of these antigen presenting cells (APC) as previously demonstrated
(Molinari et al., 2011), upregulating co-stimulatory molecules as well
as production of pro-inﬂammatory cytokines (Hervas-Stubbs et al.,
2007; Suzuki et al., 2010; Molinari et al., 2011; Quattrocchi et al.,
2013). In concordance with these ﬁndings, we have recently shown that
residual BV in the crude puriﬁed protein preparations induces TNF-α
production by monocytes/macrophages in vitro (Malm et al., 2016a).
TNF-α triggers the recruitment and activation of APCs at the injection
site and facilitates migration of APCs to lymph nodes (Stoitzner et al.,
1999), thus improving the antigen uptake and presentation to T cells.
Previous reports have demonstrated that BV enhances T cell
responses against co-administered antigens (Hervas-Stubbs et al.,
2007; Margine et al., 2012). Thus, after observing the adjuvant eﬀect
of BV on IgG2a antibody production against both antigens, we
investigated antigen-speciﬁc IFN-γ cytokine production, a hallmark
of Th1 cell immunity. BV promoted generation of T cell responses
against co-delivered antigens, as addressed by considerable secretion of
IFN-γ by splenocytes upon stimulation with OVA and NoV GII.4
derived peptides corresponding to the immunodominant CD4+ T cell
epitopes, as well as a peptide pool covering the entire sequence of NoV
VP1. Similarly to the antibody response, BV inactivation abolished the
capacity of BVs to induce OVA-speciﬁc T cell response, suggesting that
induction of T cell response is also dependent on the presence of live
BV particles. Cells of mice immunized with formulations containing
live BV, but not IBV, produced high amount of IFN-γ upon ex vivo
stimulation with BV. This indicates activation of T cells in lymphoid
tissues by BV, which is in agreement with previous observations by
others (Strauss et al., 2007; Molinari et al., 2011). Paracrine secretion
of cytokines by BV-speciﬁc T cells is of a signiﬁcance as these cytokines
drive proliferation and diﬀerentiation of co-delivered antigen primed
lymphocytes.
BV has a pronounced adjuvant eﬀect on T cell responses to NoV,
although it also improves functionality of the antibodies in terms of
avidity and blocking/neutralization. However, more pronounced B and
T cell adjuvant eﬀect was observed to co-delivered OVA antigen, which
is not surprising due to the less immunogenic nature of soluble
monomeric proteins in comparison to the more immunogenic VLPs
(Bachmann and Jennings, 2010). Superior immunogenicity of particles
or protein aggregates over soluble proteins is strongly linked to the
multivalent organization of antigen presented on particles (Bachmann
et al., 1993; Ghosh et al., 2002). Unlike soluble proteins, the larger
structures within the size range of ~40 nm are eﬃciently internalized
by APCs (Fiﬁs et al., 2004), and thus carried to the lymphoid organs
and presented to T cells.
In conclusion, the presence of live BV in antigenic formulations
strengthened both antibody and T cell immune responses to these
proteins, further sparing the dose of the antigen. Therefore, it is
tempting to speculate, that crude puriﬁed proteins could be excellent
candidates for veterinary vaccines. For instance, a vaccine containing
crude puriﬁed avian inﬂuenza antigens could be used to vaccinate wild
birds and domestic poultry to limit the potential spread of pandemic
inﬂuenza viruses, extremely harmful to human population (Noh et al.,
Fig. 7. BV-speciﬁc antibodies and T cell responses. (A) BV-speciﬁc serum IgG responses
in mice immunized with OVA alone or together with BV or IBV. Control mice received
PBS only. Shown are mean OD490 values with standard errors of the means of
termination sera. (B) BV-speciﬁc T cell responses induced in mice immunized with
diﬀerent OVA formulations. BV was used to stimulate IFN-γ production from the group-
wise pooled splenocytes of immunized and control mice. Mean IFN-γ spot-forming cells
(SFC)/106 splenocytes of duplicate wells of 1–3 independent experiments with standard
errors of the means are shown.
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2016; Pushko et al., 2017). High quantities of the vaccine stocks could
be produced relatively easy and at a low cost, without the need for time
consuming and costly chromatographic puriﬁcation steps. The residual
BV in crude puriﬁed protein preparations would alleviate the need for
addition of external adjuvants to the vaccine formulation because of the
intrinsic immunostimulatory eﬀect of live BV. Signiﬁcant advantages of
BV include its inherent inability to replicate in vertebrate cells (Tjia
et al., 1983; Brusca et al., 1986), thus eliminating the need for
inactivation, as well as low cytotoxicity and absence of pre-existing
immunity (Shoji et al., 1997; Strauss et al., 2007). Although there is a
high concern by regulatory agencies about contaminating viruses in
human vaccines, BV could be considered as an adjuvant in veterinary
vaccines due to their less stringent regulatory requirements (Adams,
2015). Because it is diﬃcult to ensure the constant level of BV in crude
protein preparations, the activity of BV in a vaccine formulation should
be evaluated by determining the range of BV concentrations (e.g.
adding exact amounts of BV into the pure VLPs) exerting adjuvant
eﬀect in carefully designed preclinical animal experiments, and thus,
each crude vaccine batch needs to be tested to meet the concentration
range. Since live BVs in vaccine formulations may provoke reactogeni-
city and raise safety concerns, further studies are needed to ascertain
the reactogenicity, toxicity and safety of BV containing vaccine
preparations in relevant animal models.
Acknowledgements
We gratefully acknowledge the technical assistance given by the
laboratory personnel of the Vaccine Research Center. Special thanks
are due to Eeva Jokela, Sanna Kavén and Marianne Karlsberg for
technical assistance. This research did not receive any speciﬁc grant
from funding agencies in the public, commercial, or not-for-proﬁt
sectors.
References
Abe, T., Hemmi, H., Miyamoto, H., Moriishi, K., Tamura, S., Takaku, H., Akira, S.,
Matsuura, Y., 2005. Involvement of the Toll-like receptor 9 signaling pathway in the
induction of innate immunity by baculovirus. J. Virol. 79, 2847–2858.
Abe, T., Takahashi, H., Hamazaki, H., Miyano-Kurosaki, N., Matsuura, Y., Takaku, H.,
2003. Baculovirus induces an innate immune response and confers protection from
lethal inﬂuenza virus infection in mice. J. Immunol. 171, 1133–1139.
Abe, T., Kaname, Y., Wen, X., Tani, H., Moriishi, K., Uematsu, S., Takeuchi, O., Ishii,
K.J., Kawai, T., Akira, S., Matsuura, Y., 2009. Baculovirus induces type I interferon
production through toll-like receptor-dependent and -independent pathways in a
cell-type-speciﬁc manner. J. Virol. 83, 7629–7640.
Adams, A., 2015. Veterinary vaccines: regulations and impact on emerging infectious
diseases. In: Milligan, G., Barrett, A. (Eds.), Vaccinology: An Essential Guide. John
Wiley & Sons, Ltd, Oxford, UK..
Atmar, R.L., Baehner, F., Cramer, J.P., Song, E., Borkowski, A., Mendelman, P.M., NOR-
201 Study Group. 2016. Rapid responses to 2 virus-like particle norovirus vaccine
candidate formulations in healthy adults: a randomized controlled trialJ. Infect. Dis.
214, 845–853.
Bachmann, M.F., Jennings, G.T., 2010. Vaccine delivery: a matter of size, geometry,
kinetics and molecular patterns. Nat. Rev. Immunol. 10, 787–796.
Bachmann, M.F., Kalinke, U., Althage, A., Freer, G., Burkhart, C., Roost, H., Aguet, M.,
Hengartner, H., Zinkernagel, R.M., 1997. The role of antibody concentration and
avidity in antiviral protection. Science 276, 2024–2027.
Bachmann, M.F., Rohrer, U.H., Kundig, T.M., Burki, K., Hengartner, H., Zinkernagel,
R.M., 1993. The inﬂuence of antigen organization on B cell responsiveness. Science
262, 1448–1451.
Blazevic, V., Lappalainen, S., Nurminen, K., Huhti, L., Vesikari, T., 2011. Norovirus VLPs
and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis. Vaccine
29, 8126–8133.
Blazevic, V., Malm, M., Arinobu, D., Lappalainen, S., Vesikari, T., 2016. Rotavirus capsid
VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a
combination vaccine. Hum. Vaccin Immunother. 12, 740–748.
Brusca, J., Summers, M., Couch, J., Courtney, L., 1986. Autographa californica nuclear
polyhedrosis virus eﬃciently enters but does not replicate in poikilothermic
vertebrate cells. Intervirology 26, 207–222.
Deal, E.M., Lahl, K., Narvaez, C.F., Butcher, E.C., Greenberg, H.B., 2013. Plasmacytoid
dendritic cells promote rotavirus-induced human and murine B cell responses. J.
Clin. Invest. 123, 2464–2474.
Fiﬁs, T., Gamvrellis, A., Crimeen-Irwin, B., Pietersz, G.A., Li, J., Mottram, P.L.,
McKenzie, I.F., Plebanski, M., 2004. Size-dependent immunogenicity: therapeutic
and protective properties of nano-vaccines against tumors. J. Immunol. 173,
3148–3154.
Ghosh, M.K., Borca, M.V., Roy, P., 2002. Virus-derived tubular structure displaying
foreign sequences on the surface elicit CD4+ Th cell and protective humoral
responses. Virology 302, 383–392.
Goodbourn, S., Didcock, L., Randall, R.E., 2000. Interferons: cell signalling, immune
modulation, antiviral response and virus countermeasures. J. Gen. Virol. 81,
2341–2364.
Gronowski, A.M., Hilbert, D.M., Sheehan, K.C., Garotta, G., Schreiber, R.D., 1999.
Baculovirus stimulates antiviral eﬀects in mammalian cells. J. Virol. 73, 9944–9951.
Harrington, P.R., Lindesmith, L., Yount, B., Moe, C.L., Baric, R.S., 2002. Binding of
Norwalk virus-like particles to ABH histo-blood group antigens is blocked by
antisera from infected human volunteers or experimentally vaccinated mice. J. Virol.
76, 12335–12343.
Hervas-Stubbs, S., Rueda, P., Lopez, L., Leclerc, C., 2007. Insect baculoviruses strongly
potentiate adaptive immune responses by inducing type I IFN. J. Immunol. 178,
2361–2369.
Huang, P., Farkas, T., Marionneau, S., Zhong, W., Ruvoen-Clouet, N., Morrow, A.L.,
Altaye, M., Pickering, L.K., Newburg, D.S., LePendu, J., Jiang, X., 2003. Noroviruses
bind to human ABO, Lewis, and secretor histo-blood group antigens: identiﬁcation of
4 distinct strain-speciﬁc patterns. J. Infect. Dis. 188, 19–31.
Huhti, L., Blazevic, V., Nurminen, K., Koho, T., Hytönen, V., Vesikari, T., 2010. A
comparison of methods for puriﬁcation and concentration of norovirus GII-4 capsid
virus-like particles. Arch. Virol. 155, 1855–1858.
Huhti, L., Tamminen, K., Vesikari, T., Blazevic, V., 2013. Characterization and
immunogenicity of norovirus capsid-derived virus-like particles puriﬁed by anion
exchange chromatography. Arch. Virol. 158, 933–942.
Josefsberg, J.O., Buckland, B., 2012. Vaccine process technology. Biotechnol. Bioeng.
109, 1443–1460.
Lappalainen, S., Vesikari, T., Blazevic, V., 2016. Simple and eﬃcient ultraﬁltration
method for puriﬁcation of rotavirus VP6 oligomeric proteins. Arch. Virol. 161,
3219–3223.
Le Bon, A., Etchart, N., Rossmann, C., Ashton, M., Hou, S., Gewert, D., Borrow, P.,
Tough, D.F., 2003. Cross-priming of CD8+ T cells stimulated by virus-induced type I
interferon. Nat. Immunol. 4, 1009–1015.
Le Bon, A., Schiavoni, G., D'Agostino, G., Gresser, I., Belardelli, F., Tough, D.F., 2001.
Type i interferons potently enhance humoral immunity and can promote isotype
switching by stimulating dendritic cells in vivo. Immunity 14, 461–470.
Lindesmith, L.C., Debbink, K., Swanstrom, J., Vinje, J., Costantini, V., Baric, R.S.,
Donaldson, E.F., 2012. Monoclonal antibody-based antigenic mapping of norovirus
GII.4-2002. J. Virol. 86, 873–883.
Malm, M., Heinimaki, S., Vesikari, T., Blazevic, V., 2017. Rotavirus capsid VP6 tubular
and spherical nanostructures act as local adjuvants when co-delivered with norovirus
VLPs. Clin. Exp. Immunol..
Malm, M., Tamminen, K., Lappalainen, S., Vesikari, T., Blazevic, V., 2016a. Rotavirus
recombinant VP6 nanotubes act as an immunomodulator and delivery vehicle for
norovirus virus-like particles. J. Immunol. Res. 2016, 9171632.
Malm, M., Tamminen, K., Vesikari, T., Blazevic, V., 2016b. Norovirus-speciﬁc memory T
cell responses in adult human donors. Front. Microbiol. 7, 1570.
Malm, M., Tamminen, K., Vesikari, T., Blazevic, V., 2016c. Type-speciﬁc and cross-
reactive antibodies and T cell responses in norovirus VLP immunized mice are
targeted both to conserved and variable domains of capsid VP1 protein. Mol.
Immunol. 78, 27–37.
Malm, M., Uusi-Kerttula, H., Vesikari, T., Blazevic, V., 2014. High serum levels of
norovirus genotype-speciﬁc blocking antibodies correlate with protection from
infection in children. J. Infect. Dis. 210, 1755–1762.
Margine, I., Martinez-Gil, L., Chou, Y.Y., Krammer, F., 2012. Residual baculovirus in
insect cell-derived inﬂuenza virus-like particle preparations enhances
immunogenicity. PLoS One 7, e51559.
Marionneau, S., Ruvoen, N., Le Moullac-Vaidye, B., Clement, M., Cailleau-Thomas, A.,
Ruiz-Palacois, G., Huang, P., Jiang, X., Le Pendu, J., 2002. Norwalk virus binds to
histo-blood group antigens present on gastroduodenal epithelial cells of secretor
individuals. Gastroenterology 122, 1967–1977.
McFarland, B.J., Sant, A.J., Lybrand, T.P., Beeson, C., 1999. Ovalbumin(323-339)
peptide binds to the major histocompatibility complex class II I-A(d) protein using
two functionally distinct registers. Biochemistry 38, 16663–16670.
Minor, P.D., 2015. Live attenuated vaccines: historical successes and current challenges.
Virology 479–480, 379–392.
Molinari, P., Crespo, M.I., Gravisaco, M.J., Taboga, O., Moron, G., 2011. Baculovirus
capsid display potentiates OVA cytotoxic and innate immune responses. PLoS One 6,
e24108.
Noh, J.Y., Park, J.K., Lee, D.H., Yuk, S.S., Kwon, J.H., Lee, S.W., Lee, J.B., Park, S.Y.,
Choi, I.S., Song, C.S., 2016. Chimeric bivalent virus-like particle vaccine for H5N1
HPAI and ND confers protection against a lethal challenge in chickens and allows a
strategy of Diﬀerentiating Infected from Vaccinated Animals (DIVA). PLoS One 11,
e0162946.
Nurminen, K., Blazevic, V., Huhti, L., Rasanen, S., Koho, T., Hytonen, V.P., Vesikari, T.,
2011. Prevalence of norovirus GII-4 antibodies in Finnish children. J. Med. Virol. 83,
525–531.
Puschnik, A., Lau, L., Cromwell, E.A., Balmaseda, A., Zompi, S., Harris, E., 2013.
Correlation between dengue-speciﬁc neutralizing antibodies and serum avidity in
primary and secondary dengue virus 3 natural infections in humans. PLoS Negl.
Trop. Dis. 7, e2274.
Pushko, P., Tretyakova, I., Hidajat, R., Zsak, A., Chrzastek, K., Tumpey, T.M.,
Kapczynski, D.R., 2017. Virus-like particles displaying H5, H7, H9 hemagglutinins
and N1 neuraminidase elicit protective immunity to heterologous avian inﬂuenza
viruses in chickens. Virology 501, 176–182.
S. Heinimäki et al. Virology 511 (2017) 114–122
121
Quattrocchi, V., Molinari, P., Langellotti, C., Gnazzo, V., Taboga, O., Zamorano, P., 2013.
Co-inoculation of baculovirus and FMDV vaccine in mice, elicits very early protection
against foot and mouth disease virus without interfering with long lasting immunity.
Vaccine 31, 2713–2718.
Reeck, A., Kavanagh, O., Estes, M.K., Opekun, A.R., Gilger, M.A., Graham, D.Y., Atmar,
R.L., 2010. Serological correlate of protection against norovirus-induced
gastroenteritis. J. Infect. Dis. 202, 1212–1218.
Rockx, B., Baric, R.S., de Grijs, I., Duizer, E., Koopmans, M.P., 2005. Characterization of
the homo- and heterotypic immune responses after natural norovirus infection. J.
Med. Virol. 77, 439–446.
Salmi, A.A., 1991. Antibody aﬃnity and protection in virus infections. Curr. Opin.
Immunol. 3, 503–506.
Shoji, I., Aizaki, H., Tani, H., Ishii, K., Chiba, T., Saito, I., Miyamura, T., Matsuura, Y.,
1997. Eﬃcient gene transfer into various mammalian cells, including non-hepatic
cells, by baculovirus vectors. J. Gen. Virol. 78 (Pt 10), 2657–2664.
Stoitzner, P., Zanella, M., Ortner, U., Lukas, M., Tagwerker, A., Janke, K., Lutz, M.B.,
Schuler, G., Echtenacher, B., Ryﬀel, B., Koch, F., Romani, N., 1999. Migration of
langerhans cells and dermal dendritic cells in skin organ cultures: augmentation by
TNF-alpha and IL-1beta. J. Leukoc. Biol. 66, 462–470.
Strauss, R., Huser, A., Ni, S., Tuve, S., Kiviat, N., Sow, P.S., Hofmann, C., Lieber, A.,
2007. Baculovirus-based vaccination vectors allow for eﬃcient induction of immune
responses against plasmodium falciparum circumsporozoite protein. Mol. Ther. 15,
193–202.
Suzuki, T., Chang, M.O., Kitajima, M., Takaku, H., 2010. Baculovirus activates murine
dendritic cells and induces non-speciﬁc NK cell and T cell immune responses. Cell.
Immunol. 262, 35–43.
Tamminen, K., Huhti, L., Koho, T., Lappalainen, S., Hytonen, V.P., Vesikari, T., Blazevic,
V., 2012. A comparison of immunogenicity of norovirus GII-4 virus-like particles and
P-particles. Immunology 135, 89–99.
Tamminen, K., Lappalainen, S., Huhti, L., Vesikari, T., Blazevic, V., 2013. Trivalent
combination vaccine induces broad heterologous immune responses to norovirus
and rotavirus in mice. PLoS One 8, e70409.
Tjia, S.T., zu Altenschildesche, G.M., Doerﬂer, W., 1983. Autographa californica nuclear
polyhedrosis virus (AcNPV) DNA does not persist in mass cultures of mammalian
cells. Virology 125, 107–117.
Vesikari, T., Blazevic, V., 2015. Norovirus vaccine: one step closer. J. Infect. Dis. 211,
853–855.
S. Heinimäki et al. Virology 511 (2017) 114–122
122
